Company intelligence / Profile preview

F3 Platform Biologics

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

F3 Platform Biologics is developing amifostine-based solutions to reduce radiation-induced genomic damage and instability (RIGDI) from CT scans and other radiation exposures. The company was planning an IPO but withdrew it on June 20, 2024.

Therapeutic areas: OtherDermatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

amifostine

Phase 2

Indications: Prevention of genomic damage from CT scan radiation exposure

Partnerships

Polsky Center for Entrepreneurship and Innovation

Beyond the preview

Go deeper on F3 Platform Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F3 Platform Biologics.

Explore the full profile